Benzinga | Oct 23, 2020 08:14AM EDT

CHF Solutions Reports Submission Of Its Patent Application To Improve Venous Blood Flow, Ultrafiltration Efficiency

CHF Solutions (NASDAQ:CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced the submission of a patent application for a new technological advance to the Aquadex SmartFlow(tm) system to promote venous blood flow in the arm of a patient.

A key advantage of Aquadex(tm) therapy is its ability to work in a safe and comfortable manner through peripheral venous access in the patient's arm rather than a central vein, a common access point with other systems. The new innovation covered by this patent application encourages blood flow in the veins of the patient's arm and is designed to improve the efficiency of ultrafiltration, leading to a shorter therapy time for the patient and fewer interventions for healthcare providers.

"At CHF Solutions, we are committed to developing innovative solutions that support medical professionals and their patients, and we invest in the protection of these innovations," said John Erb, CEO of CHF Solutions. "Our mission is to change the lives of patients suffering from fluid overload through science, collaboration, and innovation, and we continuously make moves to ensure we never lose sight of that goal."